MedPath

Efficacy of Calprotectin as A Marker For the Pathogenicity of Blastocystis Infection

Not yet recruiting
Conditions
Blastocystis Infections
Interventions
Diagnostic Test: Fecal Calprotectin ELISA kit
Registration Number
NCT05724368
Lead Sponsor
Sohag University
Brief Summary

Blastocystis which is commonly found in the gastro-intestinal tract, has been recognized as a non-pathogenic organism for a few decades. It has a variable distribution. A high prevalence has been reported in developing countries (22.1-100%).

In developed countries, the prevalence ranges from 0.5% to 23.1%. The high prevalence noted in developing countries is related to poor hygiene and lack of safe water and food .

Detailed Description

Blastocystis which is commonly found in the gastro-intestinal tract, has been recognized as a non-pathogenic organism for a few decades. It has a variable distribution. A high prevalence has been reported in developing countries (22.1-100%).

In developed countries, the prevalence ranges from 0.5% to 23.1%. The high prevalence noted in developing countries is related to poor hygiene and lack of safe water and food. The pathogenicity of Blastocystis is controversial because most patients carrying this parasite are asymptomatic. Several studies have considered Blastocystis sp. as a commensal micro-organism, while other results have showed the pathogenicity of the parasite.

Calprotectin (CP), a calcium-binding protein, comprises 60% of cytosolic protein found in neutrophils. Fecal calprotectin (F-CP) concentration is an indicator of neutrophil migration into the intestinal lumen and is associated with intestinal inflammation.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Patients from outpatient clinics, Sohag hospitals.
Read More
Exclusion Criteria
  • Patients taking antibiotics within the previous four weeks, and anti-parasitic drugs within the previous two weeks.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Group 1Fecal Calprotectin ELISA kitPatients with gastrointestinal symptoms and positive only for Blastocystis.
Group 3Fecal Calprotectin ELISA kitHealthy volunteers with neither gastrointestinal symptoms nor parasitological infections.
Group 2Fecal Calprotectin ELISA kitPatients with gastrointestinal symptoms and Blastocystis free.
Primary Outcome Measures
NameTimeMethod
level of fecal calprotectin1 month

Evaluation of fecal calprotectin inflammation levels of Blastocystis hominis in patients with gastrointestinal troubles as compared to patients with gastrointestinal troubles but without Blastocystis hominis

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath